OS Advantage of Gotistobart Over Docetaxel in Patients with anti-PD‑(L)1- and Chemotherapy-Resistant Metastatic Squamous NSCLC By Ogkologos - April 14, 2026 299 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the stage 1 of the phase III PRESERVE-003 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR FDA Approves Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic... January 8, 2024 Teen Invents ‘Resilience Bra’ To Help Breast Cancer Patients With Post-Mastectomy... June 13, 2019 Determination of the Incidence of Driver Mutations in Patients with NSCLC... March 24, 2021 Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients... April 9, 2025 Load more HOT NEWS EMA Recommends to Extend Therapeutic Indications for Crizotinib in Paediatric Patients Hiding in plain sight: How we can use immune cells to... News digest – cancer blood test, gum disease and junk food... Trial Produces Practice-Changing Findings for Some Children, Young Adults with Leukemia
